Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
TB-500 is typically chosen because it acts systemically
however, it is removed by the dialysis machine itself, necessitating post-dialysis administration
That said, there are situations where a shake as a temporary meal replacement makes sense: when you genuinely cannot eat anything solid, when you're managing a particularly bad nausea day, or when you need to hit a protein target and have no appetite for food
Onishi, P
CD is a chronic intestinal inflammation that can affect any part of the digestive tract, manifested as segmental and transmural inflammation
